Assessing the Clinical Service & Revenue Issues of the LDT Rule

By Robert Michel | From the Volume XXXI, No. 12 – September 3, 2024 Issue

BARRING INTERVENTION BY FEDERAL COURTS OR THE U.S. Congress, clinical labo…

Read More

---

Unpacking the Surprises in the FDA LDT Rule

By R. Lewis Dark | From the Volume XXXI, No. 12 – September 3, 2024 Issue

THERE ARE NOW TWO LAWSUITS IN TWO DIFFERENT COURTS CHALL…

Read More

---

September 3, 2024, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXXI, No. 12 – September 3, 2024 Issue

To challenge the federal Food and Drug Administration (FDA) final rule on laboratory developed tests (LDTs,) the Association for Molecular Pathology (AMP) filed a lawsuit on August 20, 2024, in the United States District Court for the Southern District of Tex…

Read More

---

Identifying Current Lab Trends from Labcorp & Quest Experience

By Robert Michel | From the Volume XXXI, No. 11 – August 12, 2024 Issue

CEO SUMMARY: Many different factors influence the operations of clinical laboratories in the United States today. One good source of competitive business intelligence is for lab administrators to follow the quarterly earnings calls of the nation’s two biggest public lab corporations. Wi…

Read More

---

What’s a Big Headwind for Labs? It’s the LDT Rule!

By R. Lewis Dark | From the Volume XXXI, No. 10 – July 22, 2024 Issue

…

Read More

---

Language in Draft House Bill Directs FDA to Suspend LDT Rule

By Robert Michel | From the Volume XXXI, No. 10 – July 22, 2024 Issue

THERE IS AN INTERESTING NEW DEVELOPMENT associated with the regulation of laboratory deve…

Read More

---

What Labs with LDTs Must Do to Comply with FDA’s LDT Rule

By Robert Michel | From the Volume XXXI, No. 10 – July 22, 2024 Issue

CEO SUMMARY: Until the recently filed court challenge to the Food and Drug Administration’s LDT rule succeeds or Congress intervenes with new legislation, those clinical laboratories performing laboratory developed tests (LDTs) must comply with the requirements of the new rule. This com…

Read More

---

LDT Rule Is Now a Fact! What Will Be Consequences?

By R. Lewis Dark | From the Volume XXXI, No. 8 – June 10, 2024 Issue

TODAY, THE NEW RULE FOR REGULATION OF LABORATORY DEVELOPED TESTS …

Read More

---

ACLA Files Court Challenge to FDA’s Final LDT Rule

By Robert Michel | From the Volume XXXI, No. 8 – June 10, 2024 Issue

CEO SUMMARY: Discussing the FDA’s final LDT rule, one pathologist tracking this matter wrote, “In many ways, the FDA’s plan [final LDT rule] is like the guy who gets three wishes from a genie, and he asks for unlimited wishes.” ACLA and HealthTrackRx are challenging the FDA’s �…

Read More

---

ACLA President Van Meter Discusses LDT Lawsuit

By Robert Michel | From the Volume XXXI, No. 8 – June 10, 2024 Issue

CEO SUMMARY: On July 5, the final laboratory developed test (LDT) rule issued by the federal Food and Drug Administration (FDA) takes effect. In response, the American Clinical Laboratory Association (ACLA) filed a lawsuit in federal court in Texas to challenge the FDA’s actions. In thi…

Read More

---